Product Name: CDK2 (162-170) pT165+pY168
Product Number: PE-04ASL01
Size: 200 µg      Price:15.00
1 mg      $US30.00
Peptide Name: CDK2 (162-170) pT165+pY168

Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. T165 and Y168 phosphorylation is predicted to be inhibitory for phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: EVV-pT-LW-pY-RA

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1295.3 Da

Peptide Purity Percent after Synthesis and Purification: >50

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Storage Stability: stable

Scientific Background: CDK2 is a protein-serine/threonine kinase of the CMGC group and CDK family. It is essential for meiosis, yet not essential for mitosis, although it is involved in cell cycle control. CDK2 has been observed to phosphorylate CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, and EZH2. Involved in the control of the cell cycle. Interacts with cyclins A, B1, B3, D, or E. Activity of CDK2 is maximal during S phase and G2.  Mutations resulting in reduced CAK phosphorylation at the T160 activating phosphosite include K9F, and K88E + K89V, while a L166R mutation results in reduced CAK phosphorylation and lower protein-serine/threonine phosphotransferase activity. Phosphorylation at Y179 increases phosphotransferase activity and interaction with CCNA2 (Cyclin A2). CCNA2 stimulates the catalytic activity of CDK2. Phosphorylation at T14 and Y15 inhibits phosphotransferase activity.